Austin J. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Austin J. Taylor has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Cameron Bruce Verchere
Department of Surgery, University of British Columbia
5 shared publications - Yi-Chun Chen
BC Children’s Hospital Research Institute, Vancouver, Canada
4 shared publications - Adam C. Swensen
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA
2 shared publications Annette E. Patterson
BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
2 shared publications- James M. Fulcher
Pacific Northwest National Laboratory
2 shared publications Kenny Fok
BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
2 shared publications
Latest Publications
- Open Access
- 19 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (38) , eady8048
α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion
α cells secrete proglucagon peptides to regulate nutrient metabolism. Recent findings support an α cell–to–β cell axis that is mediated by paracrine signaling through the glucagon receptor and glucagon-like peptide 1 (GLP-1) receptor in β cells. To address which proglucagon peptides stimulate insulin secretion, we developed an assay to quantify levels of GLP-1(7–36)NH 2 . We also generated three transgenic mouse lines that allow α cell-specific, inducible deletion of the genes for the two prohormone convertase enzymes that process proglucagon . Our studies reveal that both mouse and human islets contain GLP-1(7–36)NH2, but glucagon mediates α cell–to–β cell communication in mice. However, in the absence of normal production of glucagon, α cells up-regulate prohormone convertase 1 (PC1/3) to generate GLP-1 and enhance glucose tolerance. Human islets have substantially higher levels of GLP-1 than mice, which positively correlate with rates of insulin secretion. These studies show plasticity in proglucagon processing to support α cell–to–β cell communication.
- 19 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (38) , eady8048
Open Accessα cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion
α cells secrete proglucagon peptides to regulate nutrient metabolism. Recent findings support an α cell–to–β cell axis that is mediated by paracrine signaling through the glucagon receptor and glucagon-like peptide 1 (GLP-1) receptor in β cells. To address which proglucagon peptides stimulate insulin secretion, we developed an assay to quantify levels of GLP-1(7–36)NH 2 . We also generated three transgenic mouse lines that allow α cell-specific, inducible deletion of the genes for the two prohormone convertase enzymes that process proglucagon . Our studies reveal that both mouse and human islets contain GLP-1(7–36)NH2, but glucagon mediates α cell–to–β cell communication in mice. However, in the absence of normal production of glucagon, α cells up-regulate prohormone convertase 1 (PC1/3) to generate GLP-1 and enhance glucose tolerance. Human islets have substantially higher levels of GLP-1 than mice, which positively correlate with rates of insulin secretion. These studies show plasticity in proglucagon processing to support α cell–to–β cell communication.
- Open Access
- 2 April 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 861-879
A spatiotemporal proteomic map of human adipogenesis
White adipocytes function as major energy reservoirs in humans by storing substantial amounts of triglycerides, and their dysfunction is associated with metabolic disorders; however, the mechanisms underlying cellular specialization during adipogenesis remain unknown. Here, we generate a spatiotemporal proteomic atlas of human adipogenesis, which elucidates cellular remodelling as well as the spatial reorganization of metabolic pathways to optimize cells for lipid accumulation and highlights the coordinated regulation of protein localization and abundance during adipocyte formation. We identify compartment-specific regulation of protein levels and localization changes of metabolic enzymes to reprogramme branched-chain amino acids and one-carbon metabolism to provide building blocks and reduction equivalents. Additionally, we identify C19orf12 as a differentiation-induced adipocyte lipid droplet protein that interacts with the translocase of the outer membrane complex of lipid droplet-associated mitochondria and regulates adipocyte lipid storage by determining the capacity of mitochondria to metabolize fatty acids. Overall, our study provides a comprehensive resource for understanding human adipogenesis and for future discoveries in the field.
- 2 April 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 861-879
Open AccessA spatiotemporal proteomic map of human adipogenesis
White adipocytes function as major energy reservoirs in humans by storing substantial amounts of triglycerides, and their dysfunction is associated with metabolic disorders; however, the mechanisms underlying cellular specialization during adipogenesis remain unknown. Here, we generate a spatiotemporal proteomic atlas of human adipogenesis, which elucidates cellular remodelling as well as the spatial reorganization of metabolic pathways to optimize cells for lipid accumulation and highlights the coordinated regulation of protein localization and abundance during adipocyte formation. We identify compartment-specific regulation of protein levels and localization changes of metabolic enzymes to reprogramme branched-chain amino acids and one-carbon metabolism to provide building blocks and reduction equivalents. Additionally, we identify C19orf12 as a differentiation-induced adipocyte lipid droplet protein that interacts with the translocase of the outer membrane complex of lipid droplet-associated mitochondria and regulates adipocyte lipid storage by determining the capacity of mitochondria to metabolize fatty acids. Overall, our study provides a comprehensive resource for understanding human adipogenesis and for future discoveries in the field.
- 26 June 2023
- Published by American Diabetes Association in Diabetes
- Vol. 72 (9) , 1277-1288
Deletion of Carboxypeptidase E in β-Cells Disrupts Proinsulin Processing but Does Not Lead to Spontaneous Development of Diabetes in Mice
Carboxypeptidase E (CPE) facilitates the conversion of prohormones into mature hormones and is highly expressed in multiple neuroendocrine tissues. Carriers of CPE mutations have elevated plasma proinsulin and develop severe obesity and hyperglycemia. We aimed to determine whether loss of Cpe in pancreatic β-cells disrupts proinsulin processing and accelerates development of diabetes and obesity in mice. Pancreatic β-cell–specific Cpe knockout mice (βCpeKO; Cpefl/fl x Ins1Cre/+) lack mature insulin granules and have elevated proinsulin in plasma; however, glucose-and KCl-stimulated insulin secretion in βCpeKO islets remained intact. High-fat diet–fed βCpeKO mice showed weight gain and glucose tolerance comparable with those of Wt littermates. Notably, β-cell area was increased in chow-fed βCpeKO mice and β-cell replication was elevated in βCpeKO islets. Transcriptomic analysis of βCpeKO β-cells revealed elevated glycolysis and Hif1α-target gene expression. On high glucose challenge, β-cells from βCpeKO mice showed reduced mitochondrial membrane potential, increased reactive oxygen species, reduced MafA, and elevated Aldh1a3 transcript levels. Following multiple low-dose streptozotocin injections, βCpeKO mice had accelerated development of hyperglycemia with reduced β-cell insulin and Glut2 expression. These findings suggest that Cpe and proper proinsulin processing are critical in maintaining β-cell function during the development of hyperglycemia. Article Highlights: Carboxypeptidase E (Cpe) is an enzyme that removes the carboxy-terminal arginine and lysine residues from peptide precursors. Mutations in CPE lead to obesity and type 2 diabetes in humans, and whole-body Cpe knockout or mutant mice are obese and hyperglycemic and fail to convert proinsulin to insulin. We show that β-cell–specific Cpe deletion in mice (βCpeKO) does not lead to the development of obesity or hyperglycemia, even after prolonged high-fat diet treatment. However, β-cell proliferation rate and β-cell area are increased, and the development of hyperglycemia induced by multiple low-dose streptozotocin injections is accelerated in βCpeKO mice.
- 26 June 2023
- Published by American Diabetes Association in Diabetes
- Vol. 72 (9) , 1277-1288
Deletion of Carboxypeptidase E in β-Cells Disrupts Proinsulin Processing but Does Not Lead to Spontaneous Development of Diabetes in Mice
Carboxypeptidase E (CPE) facilitates the conversion of prohormones into mature hormones and is highly expressed in multiple neuroendocrine tissues. Carriers of CPE mutations have elevated plasma proinsulin and develop severe obesity and hyperglycemia. We aimed to determine whether loss of Cpe in pancreatic β-cells disrupts proinsulin processing and accelerates development of diabetes and obesity in mice. Pancreatic β-cell–specific Cpe knockout mice (βCpeKO; Cpefl/fl x Ins1Cre/+) lack mature insulin granules and have elevated proinsulin in plasma; however, glucose-and KCl-stimulated insulin secretion in βCpeKO islets remained intact. High-fat diet–fed βCpeKO mice showed weight gain and glucose tolerance comparable with those of Wt littermates. Notably, β-cell area was increased in chow-fed βCpeKO mice and β-cell replication was elevated in βCpeKO islets. Transcriptomic analysis of βCpeKO β-cells revealed elevated glycolysis and Hif1α-target gene expression. On high glucose challenge, β-cells from βCpeKO mice showed reduced mitochondrial membrane potential, increased reactive oxygen species, reduced MafA, and elevated Aldh1a3 transcript levels. Following multiple low-dose streptozotocin injections, βCpeKO mice had accelerated development of hyperglycemia with reduced β-cell insulin and Glut2 expression. These findings suggest that Cpe and proper proinsulin processing are critical in maintaining β-cell function during the development of hyperglycemia. Article Highlights: Carboxypeptidase E (Cpe) is an enzyme that removes the carboxy-terminal arginine and lysine residues from peptide precursors. Mutations in CPE lead to obesity and type 2 diabetes in humans, and whole-body Cpe knockout or mutant mice are obese and hyperglycemic and fail to convert proinsulin to insulin. We show that β-cell–specific Cpe deletion in mice (βCpeKO) does not lead to the development of obesity or hyperglycemia, even after prolonged high-fat diet treatment. However, β-cell proliferation rate and β-cell area are increased, and the development of hyperglycemia induced by multiple low-dose streptozotocin injections is accelerated in βCpeKO mice.
- Open Access
- 5 January 2023
- Published by Elsevier in Molecular Metabolism
- Vol. 68, 101667
Islet amyloid polypeptide does not suppress pancreatic cancer
- 5 January 2023
- Published by Elsevier in Molecular Metabolism
- Vol. 68, 101667
Open AccessIslet amyloid polypeptide does not suppress pancreatic cancer
- Open Access
Deletion of carboxypeptidase E in beta cells disrupts proinsulin processing and alters beta cell identity in mice
Carboxypeptidase E (CPE) facilitates the conversion of prohormones into mature hormones and is highly expressed in multiple neuroendocrine tissues. Carriers of CPE mutations have elevated plasma proinsulin and develop severe obesity and hyperglycemia. We aimed to determine whether loss of Cpe in pancreatic beta cells disrupts proinsulin processing and accelerates development of diabetes and obesity in mice. Pancreatic beta cell-specific Cpe knockout mice (β Cpe KO; Cpe fl/fl x Ins1 Cre/+ ) lack mature insulin granules and have elevated proinsulin in plasma; however, glucose-and KCl-stimulated insulin secretion in β Cpe KO islets remained intact. High fat diet-fed β Cpe KO mice showed comparable weight gain and glucose tolerance compared to Wt littermates. Notably, beta-cell area was increased in chow-fed β Cpe KO mice and beta-cell replication was elevated in β Cpe KO islets. Transcriptomic analysis of β Cpe KO beta cells revealed elevated glycolysis and Hif1α -target gene expression. Upon high glucose challenge, beta cells from β Cpe KO mice showed reduced mitochondrial membrane potential, increased reactive oxygen species, reduced MafA , and elevated Aldh1a3 transcript levels. Following multiple low-dose streptozotocin treatment, β Cpe KO mice had accelerated hyperglycemia with reduced beta-cell insulin and Glut2 expression. These findings suggest that Cpe and proper proinsulin processing are critical in maintaining beta cell function during the development of diabetes.
Open AccessDeletion of carboxypeptidase E in beta cells disrupts proinsulin processing and alters beta cell identity in mice
Carboxypeptidase E (CPE) facilitates the conversion of prohormones into mature hormones and is highly expressed in multiple neuroendocrine tissues. Carriers of CPE mutations have elevated plasma proinsulin and develop severe obesity and hyperglycemia. We aimed to determine whether loss of Cpe in pancreatic beta cells disrupts proinsulin processing and accelerates development of diabetes and obesity in mice. Pancreatic beta cell-specific Cpe knockout mice (β Cpe KO; Cpe fl/fl x Ins1 Cre/+ ) lack mature insulin granules and have elevated proinsulin in plasma; however, glucose-and KCl-stimulated insulin secretion in β Cpe KO islets remained intact. High fat diet-fed β Cpe KO mice showed comparable weight gain and glucose tolerance compared to Wt littermates. Notably, beta-cell area was increased in chow-fed β Cpe KO mice and beta-cell replication was elevated in β Cpe KO islets. Transcriptomic analysis of β Cpe KO beta cells revealed elevated glycolysis and Hif1α -target gene expression. Upon high glucose challenge, beta cells from β Cpe KO mice showed reduced mitochondrial membrane potential, increased reactive oxygen species, reduced MafA , and elevated Aldh1a3 transcript levels. Following multiple low-dose streptozotocin treatment, β Cpe KO mice had accelerated hyperglycemia with reduced beta-cell insulin and Glut2 expression. These findings suggest that Cpe and proper proinsulin processing are critical in maintaining beta cell function during the development of diabetes.
- Open Access
- 28 June 2021
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 42 (5) , 528-583
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
The pathogenesis of hyperglycemia observed in most forms of diabetes is intimately tied to the islet β cell. Impairments in propeptide processing and secretory function, along with the loss of these vital cells, is demonstrable not only in those in whom the diagnosis is established but typically also in individuals who are at increased risk of developing the disease. Biomarkers are used to inform on the state of a biological process, pathological condition, or response to an intervention and are increasingly being used for predicting, diagnosing, and prognosticating disease. They are also proving to be of use in the different forms of diabetes in both research and clinical settings. This review focuses on the β cell, addressing the potential utility of genetic markers, circulating molecules, immune cell phenotyping, and imaging approaches as biomarkers of cellular function and loss of this critical cell. Further, we consider how these biomarkers complement the more long-established, dynamic, and often complex measurements of β-cell secretory function that themselves could be considered biomarkers.
- 28 June 2021
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 42 (5) , 528-583
Open AccessThe β Cell in Diabetes: Integrating Biomarkers With Functional Measures
The pathogenesis of hyperglycemia observed in most forms of diabetes is intimately tied to the islet β cell. Impairments in propeptide processing and secretory function, along with the loss of these vital cells, is demonstrable not only in those in whom the diagnosis is established but typically also in individuals who are at increased risk of developing the disease. Biomarkers are used to inform on the state of a biological process, pathological condition, or response to an intervention and are increasingly being used for predicting, diagnosing, and prognosticating disease. They are also proving to be of use in the different forms of diabetes in both research and clinical settings. This review focuses on the β cell, addressing the potential utility of genetic markers, circulating molecules, immune cell phenotyping, and imaging approaches as biomarkers of cellular function and loss of this critical cell. Further, we consider how these biomarkers complement the more long-established, dynamic, and often complex measurements of β-cell secretory function that themselves could be considered biomarkers.
- Open Access
- 19 September 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (S2) , 64-76
Islet prohormone processing in health and disease
Biosynthesis of peptide hormones by pancreatic islet endocrine cells is a tightly orchestrated process that is critical for metabolic homeostasis. Like neuroendocrine peptides, insulin and other islet hormones are first synthesized as larger precursor molecules that are processed to their mature secreted products through a series of proteolytic cleavages, mediated by the prohormone convertases Pc1/3 and Pc2, and carboxypeptidase E. Additional posttranslational modifications including C‐terminal amidation of the β‐cell peptide islet amyloid polypeptide (IAPP) by peptidyl‐glycine α‐amidating monooxygenase (Pam) may also occur. Genome‐wide association studies (GWAS) have showed genetic linkage of these processing enzymes to obesity, β‐cell dysfunction, and type 2 diabetes (T2D), pointing to their important roles in metabolism and blood glucose regulation. In both type 1 diabetes (T1D) and T2D, and in the face of metabolic or inflammatory stresses, islet prohormone processing may become impaired; indeed elevated proinsulin:insulin (PI:I) ratios are a hallmark of the β‐cell dysfunction in T2D. Recent studies suggest that genetic or acquired defects in proIAPP processing may lead to the production and secretion of incompletely processed forms of proIAPP that could contribute to T2D pathogenesis, and additionally that impaired processing of both PI and proIAPP may be characteristic of β‐cell dysfunction in T1D. In islet α‐cells, the prohormone proglucagon is normally processed to bioactive glucagon by Pc2 but may express Pc1/3 under certain conditions leading to production of GLP‐1(7‐36 NH2 ). A better understanding of how β‐cell processing of PI and proIAPP, as well as α‐cell processing of proglucagon, are impacted by genetic susceptibility and in the face of diabetogenic stresses, may lead to new therapeutic approaches for improving islet function in diabetes.
- 19 September 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (S2) , 64-76
Open AccessIslet prohormone processing in health and disease
Biosynthesis of peptide hormones by pancreatic islet endocrine cells is a tightly orchestrated process that is critical for metabolic homeostasis. Like neuroendocrine peptides, insulin and other islet hormones are first synthesized as larger precursor molecules that are processed to their mature secreted products through a series of proteolytic cleavages, mediated by the prohormone convertases Pc1/3 and Pc2, and carboxypeptidase E. Additional posttranslational modifications including C‐terminal amidation of the β‐cell peptide islet amyloid polypeptide (IAPP) by peptidyl‐glycine α‐amidating monooxygenase (Pam) may also occur. Genome‐wide association studies (GWAS) have showed genetic linkage of these processing enzymes to obesity, β‐cell dysfunction, and type 2 diabetes (T2D), pointing to their important roles in metabolism and blood glucose regulation. In both type 1 diabetes (T1D) and T2D, and in the face of metabolic or inflammatory stresses, islet prohormone processing may become impaired; indeed elevated proinsulin:insulin (PI:I) ratios are a hallmark of the β‐cell dysfunction in T2D. Recent studies suggest that genetic or acquired defects in proIAPP processing may lead to the production and secretion of incompletely processed forms of proIAPP that could contribute to T2D pathogenesis, and additionally that impaired processing of both PI and proIAPP may be characteristic of β‐cell dysfunction in T1D. In islet α‐cells, the prohormone proglucagon is normally processed to bioactive glucagon by Pc2 but may express Pc1/3 under certain conditions leading to production of GLP‐1(7‐36 NH2 ). A better understanding of how β‐cell processing of PI and proIAPP, as well as α‐cell processing of proglucagon, are impacted by genetic susceptibility and in the face of diabetogenic stresses, may lead to new therapeutic approaches for improving islet function in diabetes.